{"nctId":"NCT00813995","briefTitle":"A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)","startDateStruct":{"date":"2008-12-09","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":395,"armGroups":[{"label":"Sitagliptin","type":"EXPERIMENTAL","interventionNames":["Drug: Comparator: Sitagliptin phosphate"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Comparator: Placebo"]}],"interventions":[{"name":"Comparator: Sitagliptin phosphate","otherNames":["GLUCOPHAGE®"]},{"name":"Comparator: Placebo","otherNames":["GLUCOPHAGE®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 18 - 78 years of age\n* Currently on metformin monotherapy\n\nExclusion Criteria:\n\n* History of Type 1 diabetes mellitus or ketoacidosis\n* Currently on a weight loss program and not in the maintenance phase or has started on a weight loss medication within the last 8 weeks\n* Has undergone surgery requiring general anesthesia within the past 4 weeks or has planned major surgery\n* Currently participating in a study or has participated in a study with or without an investigational compound or device within the past 12 weeks\n* History of active liver disease such as chronic active hepatitis B or C, cirrhosis or symptomatic gallbladder disease\n* HIV positive\n* Pregnant, breast-feeding or planning to become pregnant during the study\n* User of recreational or illicit drugs or has a recent history (within the past year) of drug or alcohol abuse or dependence","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"78 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hemoglobin A1c (A1C) at Week 24","description":"A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.02","spread":"0.99"},{"groupId":"OG001","value":"-0.14","spread":"1.22"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Hemoglobin A1c (A1C) at Week 24 for Participants on Metformin 1000 mg/Day","description":"A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.84","spread":"1.09"},{"groupId":"OG001","value":"-0.01","spread":"1.31"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Hemoglobin A1c (A1C) at Week 24 for Participants on Metformin 1700 mg/Day","description":"A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.14","spread":"0.88"},{"groupId":"OG001","value":"-0.21","spread":"1.12"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 2-hour Post-meal Glucose (PMG) at Week 24","description":"Change from baseline at Week 24 is defined as Week 24 minus Week 0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-43.4","spread":"57.3"},{"groupId":"OG001","value":"-10.0","spread":"60.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24","description":"Change from baseline at Week 24 is defined as Week 24 minus Week 0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.3","spread":"39.1"},{"groupId":"OG001","value":"0.5","spread":"40.1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":197},"commonTop":["UPPER RESPIRATORY TRACT INFECTION"]}}}